CMB International: Initiate coverage on Kangnova-B (02162.HK) with a "Buy" rating and a target price of HK$82.

According to the Wise Finance APP, China Merchant Securities issued a research report stating that it has initiated coverage on CanSino Biologics Inc. -B (02162.HK) for the first time, with a "buy" rating and a target price of HK$82. They believe that the market is currently undervaluing CanSino's long-term development potential. The bank expects its annual operating income to be 610 million, 1.08 billion, and 1.97 billion RMB for the years 2025 to 2027.